Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved WYNZORA®, a white uniform cream containing 0.05 mg/g of calcip
(Financial Post, 2025-12-18T12:33:58Z)